GENE ONLINE|News &
Opinion
Blog

2018-05-15|

May 14, 2005: Piggybac as a Genetic Manipulation Tool for Analyzing Vertebrates, Patent Application Submitted to WIPO

by GeneOnline
Share To

The PiggyBac (PB) transposon is a mobile genetic element that can transpose between vectors and chromosomes via a “cut and paste” mechanism, and thus PiggyBac is an important tool related to transgenic technique. One specific technique using Piggybac as a tool for genetic manipulation and analysis in vertebrates was previously granted by the patent offices in the US, Europe, Canada, Japan, and China. On May 14, 2005, the inventors submitted a patent application to the World Intellectual Property Organization (WIPO) for this technique. Using PB transposon to transfer targeted gene fragment from vector into chromosome can effectively transplant targeted gene into the gene of certain organisms. In addition, PiggyBac technology is also equipped with a unique reversible characteristic.

Reference
http://europepmc.org/patents/PAT/CA2608481
https://en.wikipedia.org/wiki/PiggyBac_Transposon_System

Image Source
https://www.systembio.com/products/gene-expression-systems/piggybac-transposon/

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
US Court Rules Novartis Blockbuster Multiple Sclerosis Drug’s Patent Invalid
2022-06-22
Bristol Myers Squibb Requests $1.2 Billion Patent Revival From Supreme Court
2022-06-17
Illumina to Pay BGI $333M Following Infringement Case
2022-05-09
LATEST
Topo-1 and FRα: Key Focus Areas and Major Collaborations in ADC Research – Part I
2024-07-23
Eli Lilly’s Tirzepatide Gets Approval in China for Weight Loss Management
2024-07-22
Roche Reports Positive Clinical Trial Results for Two Diabetes-Related Eye Disease Therapies
2024-07-19
7th Person in History Possibly Cured From HIV After Stem Cell Transplant for Acute Myeloid Leukemia
2024-07-19
Large RCT Finds Time-Lapse Imaging for Embryo Selection in IVF Does Not Improve Live Birth Rates
2024-07-19
Assessment of Supply Chain Risk Key to Improving Medicine Access
2024-07-18
SK Biopharma and Full-Life Sign US$571.5 Million Deal for Innovative Radiopharmaceutical FL-091
2024-07-18
EVENT
Scroll to Top